H eparin-induced thrombocytopenia (HIT) is a severe drug adverse effect with possible dramatic consequences. 1 It is characterized by a substantial decrease in platelet count up to a level of 50% or less of its initial value after heparin administration. Heparin-induced thrombocytopenia typically Heparin-induced thrombocytopenia is a severe drug adverse effect with possible dramatic consequences. The risk is 0.1% to 5%. The costs of heparin-induced thrombocytopenia in France were estimated using the Programme Médicalisé des Systèmes d'Information (PMSI) national discharge database. Hospitalizations with heparin-induced thrombocytopenia were identified using diagnostic codes. Costs were assessed from the perspective of the French Sickness Fund or hospitals. Heparin-induced thrombocytopenia could be the reason of admission or could occur during the stay and lead to a different tariff or to additional costs associated with extra length of stay. Direct costs were also estimated from experts' opinions. A sensitivity analysis was performed from data collected in 1 center. During 2005, 445 hospitalizations with heparin-induced thrombocytopenia codes were identified. For 45 patients, the main diagnosis was heparin-induced thrombocytopenia; for the remaining 400 patients, heparin-induced thrombocytopenia occurred during the hospital stay. Tariffs and extra costs were used to estimate an overall average cost of €3230 for heparin-induced thrombocytopenia. For patients with heparin-induced thrombocytopenia as main diagnosis, the average cost was €3400; for the patients with heparin-induced thrombocytopenia that occurred during the stay, €1910 was due to an increased of the tariff and €3348 to an increased length of stay. Estimated direct costs of an episode were €3350 to €3700. Different methods were used to arrive at an estimated cost of €3500 for a heparininduced thrombocytopenia episode for inpatients. One limitation of the study is that heparin-induced thrombocytopenia tends to be underreported by physicians during hospitalization. syndrome, with a high incidence of both arterial and venous thrombosis.
Therapeutic management of HIT patient is an emergency, because a delay in treatment can result in life-threatening complications. Clinical management includes prompt withdrawal of heparin and its replacement with a suitable alternative. Substitution with any low-molecular-weight heparin (LMWH) is contraindicated in HIT. Treatment may include danaparoid sodium or direct thrombin inhibitors.
Depending on the surgical or medical clinical context, the estimated HIT incidence rate after the administration of unfractionated heparin was 1% to 5%. 3, 4 A lower incidence rate of 0.1% to 1% has been estimated for LMWH. 5, 6 New synthetic anti-Xa anticoagulant agents, such as fondaparinux, are less likely to be associated with HIT. 7 An excess of risk for female patients has been recently reported. 8 Furthermore, 1 study reported that preexposure to heparin increased by 5-fold the risk of HIT in a medical context. 6 Because heparin prescriptions, especially LMWH, are increasing due to an increase in the number of indications for patients at moderate or high risk of a thrombotic event, such as medical patients confined to bed, the potential number of HIT cases will likely increase.
Economic consequences of HIT management have rarely been investigated. Two North American studies estimated the average cost of hospitalization with HIT. The first study 9 found the cost of hospitalization was $56 000 for a patient with HIT compared with $15 000 for a patient without HIT. The second study 10 estimated the cost of HIT at $3300 more. In this study, we estimated the average cost of HIT in the French hospitals using 2 methods: one based on an analysis of the national discharge database and the other based on an analysis of data from a single center.
Material and Methods
The aim of this study was to estimate the average cost of an HIT episode in French hospitals with the perspective of the French Sickness Fund. Inpatients with HIT included those hospitalized with HIT as the main diagnosis at admission and those admitted for another reason who later presented with HIT during the course of hospitalization.
Our study was performed in 2 phases. The first phase consisted of an analysis of the National French Inpatients Database, Programme Médicalisé des Systèmes d'Information (PMSI), corresponding to all the hospitalizations that occurred during the year 2005 in the French hospitals. This database is exhaustive and involves more than 20 million hospitalizations in French acute-care hospitals. For each hospitalization, available information includes sex, age, main and secondary diagnoses (International Classification of Diseases and Related Health Problems, 10th Revision [ICD-10] codes), 11 length of stay (LOS), diagnosis-related group, called HGS (Homogeneous Group of Hospital Stays), medical procedures, and mode of discharge.
Private and public hospitals in France charge the French Sickness Fund according to their case mix of HGS. National tariffs or fares from HGS are regularly updated. 12 The HGS for the hospital stays is based both on the procedures performed and on the diagnoses. For a given HGS, hospitalizations are split by those without and those with medical complications according to the codes for secondary diagnoses. There is a list 12 of secondary diagnoses related to HGS with complications for a given main diagnosis. Tariffs for HGS with or without medical complication are very different. Lastly, in case of patient allocation to a specific HGS with a longer stay than a given upper limit, hospitals charge a daily cost for each day over this limit. These extra daily costs are fixed for each HGS.
The analysis was done by following 3 steps ( Figure 1 ):
1. Selection of all the hospital stays with a diagnosis of HIT. Two ICD-10 codes were selected for thrombocytopenia and another code for the relationship with an anticoagulant drug other than vitamin K antagonist because there is no single ICD-10 code for HIT. Cases were selected if they had 1 code for thrombocytopenia (a or b) and the code for complications was linked to an anticoagulant agent (c): a. D69.5 = Secondary thrombocytopenia b. D69.6 = Thrombocytopenia, unspecified c. Y442 = Complications of medical and surgical care linked to anticoagulants 2. Categorization of hospitalizations.
a. Hospitalizations with 1 of the 2 thrombocytopenia codes as the main diagnosis were considered to be directly related to HIT; b. Hospitalizations with another main diagnosis and an HGS with medical complications; in this situation, we analyzed all the secondary diagnoses and subdivided again these cases in 2 groups:
• Hospitalizations with no other secondary diagnosis that could allocate the stay to a HGS with medical complications. In other words, hospitalization for which HIT was the only noted complication. Then the HIT cost was estimated to be the difference between the HGS with and the HGS without medical complications. The second phase of the study was performed in one hospital.
During the period between January 1, 2005, and December 31, 2005, we identified through the PMSI all patients whose hospital stay was associated with the predefined ICD-10 codes. Moreover, all patients with a diagnosis of HIT objectively confirmed by tests performed in the centralized hematology laboratory were identified. This information was used to estimate the ratio of HIT patients correctly coded as such in the PMSI database and to compare the costs of the HGS in the 2 groups.
A sensitivity analysis was performed using an estimate of costs directly related to HIT. The calculation of extra daily costs for HIT was performed using daily hospital costs of the HGS by removing the costs of medical care (physicians, nurses, medications, examinations) and adding an estimate of the resources 
Results

Phase 1⎯ ⎯PMSI Database Analysis
A total of 50 958 stays had a diagnosis that included at least 1 of the thrombocytopenia codes. Among these, 6536 had a thrombocytopenia code as primary diagnosis. Association with the anticoagulant code Y44.2 was found in only 445 stays. These 445 stays included 45 stays with thrombocytopenia as the primary diagnosis and 400 with thrombocytopenia as a secondary diagnosis.
The characteristics of the 45 hospitalized patients with a main diagnosis of thrombocytopenia were 69% men, with a mean age of 68.2 (SD, 14.2) years and 62% aged older than 65 years. A breakdown of the stays showed that 75% were in the public sector, 82.2% of patients came directly from home, and 17.8% were referred from another hospital. Discharge was to home for 66.7% of the patients, referral to another hospital or ward for 28.9%, and 4.4% died. The average LOS was 7 ± 6.8 days.
For the 400 patients with a secondary diagnosis of thrombocytopenia, 53.3% were men with a mean age of 70.5 (SD, 14.2) years. Most of these stays (77.5%) were in a public hospital, and 88.5% of patients came directly from home; only 10.5% were referred from another hospital. Discharge was to home in 57.0% of the patients, 30% were referred to another department, and 13.0% died. The average LOS was 18.0 (SD, 14.0) days.
The most frequent HGSs are reported in Table 1 , indicating the large variability of medical situations in which HIT was suspected.
Determination of Hospitalization Costs
Patients with HIT as the main diagnosis. The calculation of hospitalization costs for the 45 patients admitted with a main diagnosis of HIT is presented in Table 2 . The average cost per hospitalization was estimated at €3400 for these patients.
Patients with HIT as a secondary diagnosis. For the 400 hospitalizations with a secondary diagnosis of HIT, we identified three different categories:
• 38 hospitalizations with an associated medical complication (AMC) and HIT as the only secondary diagnosis leading to AMC; • 280 hospitalizations with AMC that included HIT and other secondary diagnoses leading to AMC; • 82 hospitalizations without AMC;
In the first category in which HIT was taken into account for the tariff, the 38 hospitalizations were allocated to 27 different HGS. Their average cost was estimated at €5684 instead of €3774 if HIT had not occurred; therefore, the extra cost of HIT can be estimated at €1910 per hospitalization.
The extra costs due to HIT for the 362 hospitalizations of the second and third categories where HIT was estimated on the basis of the additional LOS was mainly supported by the hospital. The 362 hospitalizations were classified in 126 different HGS. The overall average extra LOS was 6.72 days, and the hospitalization 
Estimation of a Mean HIT Cost
Mean costs due to HIT during hospitalization were estimated using 3 calculation methods as reported in Table 3 .
Phase 2⎯ ⎯Quality Control in the University Hospital of Brest
Of the PMSI data among 33 812 hospitalizations episodes during the study period, 9 patients were identified with HIT codes, as previously defined. Among these 9, laboratory test results were positive for 7 and 1 died. In addition, 26 patients with a positive test result for HIT were not coded as HIT cases in the PMSI system. Two of these patients died. The PMSI system had only registered approximately 20% of the HIT cases in the Brest Hospital. The average cost related to the stays identified through the PMSI system with declared HIT cases was €31 107 in comparison with the costs of stays linked to HIT as identified by laboratory testing, which were only €19 865.
Sensitivity Analysis
The hospital expenses associated with an episode of HIT were estimated for the diagnosis, with the treatment during a mean period of 7 to 10 days corresponding to the clinical guidelines and a standard follow-up. These data are presented in Table 4 .
Direct costs of a HIT episode managed in the hospital were estimated at €1200 to €1700. Average hostel costs associated with the additional LOS due to HIT based on a daily cost excluding any further medical care was calculated at about €2260. Thus, the overall average costs due to a secondary diagnosis of HIT and its management was €3500 ( Table 5 ).
Discussion
We estimated the average cost of an HIT episode by using information collected in the French hospital database and the official national tariffs. On the basis of the 445 hospitalizations with HIT identified during 2005, the average cost represents approximately €3230, which is mainly paid by the hospitals.
A sensitivity analysis excluding the medical costs from hospital daily costs and adding costs of an episode based on clinical guidelines estimated the average costs ranged between €3350 and €3700. An important part of these costs is due to the medications used to replace heparin, between €950 and €1300. The extra LOS due to HIT occurring during the course of hospitalization and the LOS of hospitalizations due to HIT patients was an average of 7 days. This duration corresponds approximately to the mean duration of a treatment of an HIT episode.
The main limit of our study is that physicians are likely to underreport HIT in the PMSI database by not using the proper codes. This was shown by the analysis of Brest Hospital data, which identified 20% of the HIT retrieved by biologic testing. It may be that only severe episodes of HIT were properly coded, but because of the limited number of cases in the Brest Hospital analysis, no firm conclusion can be drawn at this point. For the analysis based on PMSI, using ICD-10 codes does not allow confirmation of the diagnosis. However, when HIT is strongly suspected, whether or not complicated with thrombosis, a nonheparin alternative coagulation should be initiated without waiting for laboratory test results.
The evaluation method we used for the patients with HIT as a secondary diagnosis is highly conservative. When a stay had a lower LOS than the average, we counted the "benefit" for the hospital with negative extra costs.
Finally, to the best of our knowledge, only 2 North American studies, 9, 10 and no European study, has previously estimated the costs due to HIT. The first estimate of average extra costs was very high, at about $41 000 per episode, obtained in a casecontrol study. 9 In this retrospective study, 44 HIT cases of adult medical patients (treated with argatroban or lepirudin or a positive enzyme-linked immunosorbent assay for heparin-dependent antiplatelet antibodies) were matched by age, ward, and ICD class as the main diagnosis at admission with 4 or 5 control patients. Costs of HIT patients were estimated NOTES: ELISA = enzyme-linked immunosorbent assay; HIT = heparin-induced thrombocytopenia; Ac anti-PF4-Hep = anti-platelet factor 4 heparin antibodies to be approximately 4 times higher than costs of the controls ($56 364 vs $15 231).
The second study was based on a database of 509 hospitals and was a retrospective chart review of hospitalizations coded with HIT and costs after hip or knee replacement or hip fracture surgery. These authors compared the costs of HIT patients (treatment group) with patients hospitalized for orthopaedic surgery and not receiving any injectable anticoagulant (no treatment group). The study population included 144 806 patients, and the incidence of HIT was 1.7% (approximately 2500 HIT cases). The authors estimated that HIT accounted for an adjusted cost increase of 22% ($19 134 vs $15 400) and an average additional LOS of 2.7 days.
The difference in the estimated costs of the 2 studies could be explained by their design, by the severity of the cases that were probably higher in the first study, and by the difference of the study populations (medically ill patients vs orthopedic patients).
Further studies are needed to provide an appropriate estimation of HIT costs in more specific local conditions.
